Stockscreener 앱 받기
1.50
5.63%
0.08
시간 외 거래:
1.50
전일 마감가:
$1.42
열려 있는:
$1.43
하루 거래량:
365.47K
Relative Volume:
0.78
시가총액:
$63.36M
수익:
$90.50M
순이익/손실:
$-54.00M
주가수익비율:
-1.1282
EPS:
-1.3296
순현금흐름:
$-32.90M
1주 성능:
+16.28%
1개월 성능:
-10.71%
6개월 성능:
-6.83%
1년 성능:
-69.51%
1일 변동 폭
$1.41
$1.5099
1주일 범위
$1.235
$1.5101
52주 변동 폭
$1.13
$5.459
풀몬스 Stock (LUNG) Company Profile
명칭
Pulmonx Corp
전화
650-364-0400
주소
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.50 | 59.98M | 90.50M | -54.00M | -32.90M | -1.3296 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
풀몬스 Stock (LUNG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | 개시 | D. Boral Capital | Buy |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-06-04 | 개시 | Lake Street | Buy |
| 2024-02-23 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | 개시 | Craig Hallum | Buy |
| 2023-02-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | 개시 | Citigroup | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Neutral |
| 2021-03-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-26 | 개시 | BofA Securities | Buy |
| 2020-10-26 | 개시 | Canaccord Genuity | Buy |
| 2020-10-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-10-26 | 개시 | Stifel | Buy |
| 2020-10-26 | 개시 | Wells Fargo | Equal Weight |
모두보기
풀몬스 주식(LUNG)의 최신 뉴스
Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast - Stock Titan
Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside? - AD HOC NEWS
LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - Sahm
How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - Yahoo Finance
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com
Rate Hike: Is Pulmonx Corporation stock trending bullishWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan
If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan
How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther - AD HOC NEWS
Growth Value: Should I set a stop loss on Pulmonx CorporationBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Pulmonx Corporation 2025 Annual Report: Innovative COPD Solutions, Zephyr Valve Clinical Data, and Global Market Strategy - Minichart
LUNG Technical Analysis & ETF Price Forecast - Intellectia AI
Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable - Stock Titan
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative
Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed - Stock Titan
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript - Insider Monkey
Pulmonx (LUNG): Canaccord Genuity Maintains Buy Rating, Lowers P - GuruFocus
LUNG: Analyst Jason Kolbert Maintains 'Buy' Rating with $14 Targ - GuruFocus
Pulmonx (NASDAQ:LUNG) Given "Buy" Rating at D. Boral Capital - MarketBeat
Pulmonx Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic - GuruFocus
Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock - MarketBeat
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips By Investing.com - Investing.com South Africa
Pulmonx (LUNG) general counsel sells shares, receives 150,000 RSU grant - Stock Titan
[Form 4] Pulmonx Corp Insider Trading Activity - Stock Titan
Pulmonx Q4 Earnings Call Highlights - Yahoo Finance
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Pulmonx closes $60M credit facility with Perceptive Advisors - Investing.com
Pulmonx closes $60 million credit facility with Perceptive - Investing.com
Pulmonx (LUNG) Q4 2025 Earnings Call Transcript - AOL.com
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Pulmonx (LUNG) Exceeds Q4 Revenue Expectations with Strategic Gr - GuruFocus
Pulmonx earnings beat by $0.14, revenue fell short of estimates - Investing.com
Pulmonx Corporation Reports Fourth Quarter and Full Year 2025 Financial Results, Highlights Transition and Strategic Focus for 2026 - Quiver Quantitative
Earnings Summary: Pulmonx Q4 - Benzinga
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan
Pulmonx Announces Closing of up to $60 Million Credit Facility - Yahoo Finance
Earnings Preview For Pulmonx - Benzinga
LUNG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LUNG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Bitget
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News - GuruFocus
Pulmonx's (LUNG) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
풀몬스 (LUNG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.40%
0.00%
자본화:
|
볼륨(24시간):